Cargando…
Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19
BACKGROUND: Inhaled pulmonary vasodilators are used as adjunctive therapies for the treatment of refractory hypoxemia. Available evidence suggest they improve oxygenation in a subset of patients without changing long-term trajectory. Given the differences in respiratory failure due to COVID-19 and “...
Autores principales: | Sonti, Rajiv, Pike, C. William, Cobb, Nathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724253/ https://www.ncbi.nlm.nih.gov/pubmed/33234007 http://dx.doi.org/10.1177/0885066620976525 |
Ejemplares similares
-
The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary Due To COVID-19: a Case Series
por: Imtiaz, Komal, et al.
Publicado: (2021) -
HIGH-FLOW NASAL CANULA AND INHALED EPOPROSTENOL RESPONSE IN COVID-19
por: KHURANA, NEHARIKA, et al.
Publicado: (2022) -
UTILIZING COMBINATION THERAPY WITH INHALED EPOPROSTENOL AND LOOP DIURETICS IN ACUTE HYPOXIC RESPIRATORY FAILURE FROM COVID-19
por: PINO, MARI-ELENA, et al.
Publicado: (2022) -
A Comparison of Inhaled Epoprostenol in Patients With Acute Respiratory Distress Syndrome and COVID-19-Associated Acute Respiratory Distress Syndrome
por: Robinson, John, et al.
Publicado: (2022) -
COMPARISON OF HIGHER VERSUS LOWER DOSE STEROID ADMINISTRATION IN PATIENTS WITH COVID-19 AND ACUTE HYPOXEMIC RESPIRATORY FAILURE ON INHALED EPOPROSTENOL
por: RIEGO, MARIA ATHENA, et al.
Publicado: (2022)